The Comparative Effectiveness Dementia & Alzheimer's Registry

Enrolling by invitation

Conditions studied: Alzheimer Disease, Mild Cognitive Impairment

In brief

To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.

Key facts

Study ID

NCT03687710

Run by

Weill Medical College of Cornell University

People needed

452

Starts

2015-02-16

Expected to finish

2028-06-30

Last updated by the study team

2026-03-30

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years of age or older
• family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other conditions

You may not qualify if…

• none

Where it is running

• Weill Cornell Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.